Cart
sales@molnova.com
Roxifiban acetate
CAS No. 176022-59-6
Roxifiban acetate( —— )
Catalog No. M34020 CAS No. 176022-59-6
Roxifiban acetate（DMP 754 acetate） is a potent GP IIb / IIIa antagonist that exhibits antiplatelet aggregation activity via immune mediation and can be used in the study of human thrombocytopenia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 426 | In Stock |
|
| 5MG | 667 | In Stock |
|
| 10MG | 826 | In Stock |
|
| 25MG | 1093 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRoxifiban acetate
-
NoteResearch use only, not for human use.
-
Brief DescriptionRoxifiban acetate（DMP 754 acetate） is a potent GP IIb / IIIa antagonist that exhibits antiplatelet aggregation activity via immune mediation and can be used in the study of human thrombocytopenia.
-
DescriptionRoxifiban acetate（DMP 754 acetate） is a potent GP IIb / IIIa antagonist that exhibits antiplatelet aggregation activity via immune mediation and can be used in the study of human thrombocytopenia.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorIntegrin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number176022-59-6
-
Formula Weight507.54
-
Molecular FormulaC23H33N5O8
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(C)(O)=O.C(C(NC[C@H](NC(OCCCC)=O)C(OC)=O)=O)[C@H]1CC(=NO1)C2=CC=C(C(=N)N)C=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Fibronectin CS1 Pept...
he connecting segment 1 (CS-1) is a cell attachment domain located in the type III homology connecting segment (IIICS) of fibronectin. CS1 peptide of fibronectin, which lacks the Arg-Gly-Asp-containing domain, actively inhibits tumor metastases in spontaneous and experimental metastasis models. The use of Fibronectin CS1 Peptide might offer a promising therapeutic approach for combating and preventing cancer metastasis.
-
Integrin-IN-27
A potent integrin αvβ3 antagonist with IC50 of 18 nM; could be conjugated to paclitaxel for selective delivery to alphavbeta3 positive metastatic cancer cells.
-
Cilengitide
Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.
